Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway

Table 1 Curcumin an anticancer agent in several tumors

Type of cancer	Actions	Type of study	References
Benign prostatic hypertrophy	Improved quality of life, reduced symptoms	Pilot product evaluation study	[29]
Breast	Inhibition cancer progression, decreased levels of VEGF	Phase I clinical trial	[30]
Chronic myeloid leukemia	Reduction of nitric oxide levels	Randomized controlled trial	[31]
Colorectal	Decrease inflammation (TNF-α), increase p53	Phase I clinical trial	[32]
Colorectal	Reduction in tumor growth	Phase I clinical trial	[33]
Colorectal	Decrease PGE2 levels	Phase I clinical trial	[34]
Colon carcinoma	Growth inhibition	Randomized controlled trial	[35]
Intestinal adenoma	Diminution of adverse effects	Randomized controlled trial	[36]
Pancreatic	Inhibition of toxicity profile of tumors	Phase II clinical trial	[37]
Pancreatic	Diminution of NF-ϰB pathway	Phase I clinical trial	[38]
Prostate	Increase survival	Randomized controlled trial	[39]
Prostate	Enhanced antiproliferative efficacy and targeting	Randomized controlled trial	[40]
Ovarian carcinoma	Increased cytotoxicity	Randomized controlled trial	[41]
Head and neck squamous cell carcinoma	Decrease inflammatory mediators	Randomized controlled trial	[42]

ISSN: 1756-9966